More tools:Markets·Screener·Research·Chat

Keros Therapeutics, Inc. Common Stock (KROS) Financial Statements

Keros Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00H1HP9H8
XNAS · usd
11.34▲ 0.17 (1.48%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close11.17
Day's Range10.98 – 11.31
52-Week Range9.69 – 22.55
Volume72.0K
Avg Volume191.2K
Share Statistics
Shares Outstanding
Employees78
ExchangeXNAS
Listed2020-04-08
Share count as of July 27, 2026
Loading Income Statement…
Key questions about Keros Therapeutics, Inc. Common Stock (KROS)
What is Keros Therapeutics, Inc. Common Stock's Market Cap?
Keros Therapeutics, Inc. Common Stock's Market Cap is $224.7M, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's Enterprise Value?
Keros Therapeutics, Inc. Common Stock's Enterprise Value is -$32.9M, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's Price / Sales?
Keros Therapeutics, Inc. Common Stock's Price / Sales is 15.0×, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's EV / Revenue?
Keros Therapeutics, Inc. Common Stock's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's EV / EBITDA?
Keros Therapeutics, Inc. Common Stock's EV / EBITDA is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's Revenue (TTM)?
Keros Therapeutics, Inc. Common Stock's Revenue (TTM) is $15.0M, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's Net Income (TTM)?
Keros Therapeutics, Inc. Common Stock's Net Income (TTM) is -$83.2M, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's EBITDA?
Keros Therapeutics, Inc. Common Stock's EBITDA is -$99.9M, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Keros Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -4.19, based on as-reported figures from SEC (XBRL) filings.
What is Keros Therapeutics, Inc. Common Stock's EBITDA Margin?
Keros Therapeutics, Inc. Common Stock's EBITDA Margin is -665.2%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
REVENUE:
Total revenue
YoY growth-100.0%-99.8%-87.3%+3575.8%
OPERATING EXPENSES:
Research and development
General and administrative
Total operating expenses
% of revenue—-7151.0%-7702.6%-207.9%
INCOME (LOSS) FROM OPERATIONS
% of revenue—-7051.0%-7602.6%-107.9%
OTHER INCOME (EXPENSE), NET
Dividend income
Other expense, net
Total other income, net
Income (loss) before income taxes
Income tax (provision) benefit
Net income (loss)
% of revenue—-6459.9%-6093.8%-51.0%
Net income (loss) attributable to common stockholders - basic
Net income (loss) attributable to common stockholders - diluted
Net income (loss) per share of common stock — basic (in USD per share)
Net income (loss) per share of common stock — diluted (in USD per share)